IBM: Quantum Advantage is a Matter of Business Readiness, Not Technology
An important shift is brewing in the world of quantum computing. The IBM Institute for Business Value has released a fresh report, "Journey to Quantum Advantage," which overturns the conventional understanding of quantum supremacy. Instead of a race for abstract records, the corporation offers a pragmatic view: quantum advantage is not a single milestone for everyone, but the ability to solve specific business problems more accurately, faster, and cheaper than classical methods.
What drives business?
The study, based on interviews with leaders from aerospace, finance, biomedicine, energy, and the public sector, identified three main motivators for adopting quantum technologies. 60% of companies seek solutions for complex problems, 55% are preparing their computing strategy for future changes, and 54% aim to accelerate innovation. This indicates that the market is moving from theoretical discussions to practical evaluation.
However, the path is fraught with challenges. The main barriers identified are: an acute shortage of quantum specialists (61%), the immaturity of the technology itself (56%), and unclear timelines for the emergence of real-world application scenarios (46%). As you can see, the problem lies not only in the "hardware" but also in the lack of expertise and a clear understanding of return on investment.
Real-world cases: from aircraft to the genome
Major players are already placing their bets. Boeing sees potential in quantum chemistry and materials science for aircraft design and certification. Vanguard has been testing hybrid approaches since 2022 to combat money laundering and optimize portfolios, emphasizing that advantage only makes sense when it helps clients. E.ON and Bosch, having gone through pilots, faced the limitations of noisy devices and shifted their focus to long-term preparation for fault-tolerant systems.
The biomedical sector is particularly interesting. Yonsei University uses quantum resources in tandem with supercomputers to study mitochondrial processes. Meanwhile, the Quantum Pangenomics project has already loaded the complete genome of the hepatitis D virus onto the 156-qubit IBM Heron processor. Reducing drug development timelines by even 10-20% represents a colossal breakthrough for the industry.
The ecosystem as a key factor
IBM emphasizes that every second "quantum-ready" organization participates in partnerships. Volkswagen, Chicago State University, Bradesco — these are just the tip of the iceberg. The current stage of the market is a period of experimentation and competency building. Quantum advantage will not arrive tomorrow for all industries simultaneously, but those who start preparing their infrastructure and teams today will gain a tremendous competitive advantage tomorrow.
My comment: The IBM report clearly signals that the era of "quantum marketing" is ending. Now, the focus is on specific business metrics. For the crypto industry, this is a dual signal — on one hand, a threat to current cryptographic standards, and on the other, an opportunity to create fundamentally new, quantum-resistant protocols. The question is not "if," but "who will adapt first."